The effect of a 1-week administration of cetirizine on the chemotaxis and superoxide anion production of neutrophils from healthy volunteers.
The aim of the present investigation was to examine the effect of a 1-week oral administration of the anti-allergic drug cetirizine on healthy volunteer neutrophil chemotaxis and superoxide anion (O2-) production. Eight male volunteers were selected after clinical examination and laboratory tests. Neutrophils were isolated from peripheral blood using a discontinuous density gradient. Spontaneous migration and platelet activating factor (PAF, 10(-6) and 10(-8) M) or zymosan-activated plasma (ZAP)-induced chemotaxis were studied in a 48-well microchemotaxis chamber. Basal and phorbol 12-myristate 13-acetate (PMA, 30 nM) stimulated O2- production were measured spectro-photometrically. Cetirizine (10 mg per day) was given orally during 1 week. Both neutrophil chemotaxis and O2- production were assessed before and 2 h, 24 h, and 1 week after orally administered cetirizine. Plasma cetirizine levels were monitored by high performance liquid chromatography (HPLC) with ultraviolet detection. Spontaneous neutrophil migration and PAF-or ZAP-induced chemotaxis showed no significant variation before or at various intervals after the initiation of treatment with cetirizine. Basal and PMA-stimulated neutrophil O2-production was also not affected by cetirizine. The maximum concentration attained by cetirizine (Cmax) was 293 +/- 38 ng/ml and generally peaked (Tmax) within 1.9 +/- 0.7 h. We conclude that the administration of cetirizine for 1 week does not alter human neutrophil chemotaxis and O2- production.
Condino-Neto
A
A
Department of Pediatrics, Faculty of Medical Sciences, State University of Campinas, Brazil.
Muscara
M N
MN
Bozza
P T
PT
Castro-Faria-Neto
H C
HC
De Nucci
G
G
D000328:Adult; D017332:Cetirizine / Q000097:blood / Q000494:pharmacology*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D006634:Histamine H1 Antagonists / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D013481:Superoxides / Q000097:blood*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D006634:Histamine H1 Antagonists; D013481:Superoxides; D013755:Tetradecanoylphorbol Acetate; D017332:Cetirizine